Imugene Limited Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019 31/01/2020 10:15:00 Key Highlights: Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019 Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy S…
Imugene PD1-Vaxx Immunotherapy Update 28/01/2020 09:25:00 Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx w…
Imugene HER-Vaxx Immunotherapy Patent Granted in United States 14/01/2020 09:46:00 Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application…
Market Reports / by Melissa Darmawan - 4 days ago Recession fears trigger equities rout, leaving retailers in the dust: ASX closes 1.7% lower 19 May 2022 - More pain for investors as a wave of selling on recession and inflation fears exacerbated by profit misses from retail giants Target and Walmart hit US markets, with …
Market Reports / by Melissa Darmawan - 4 days ago Jobless rate to 3.9%, Aristocrat jumps as retailers tumble, inflation haunts: ASX dives 1.5% at noon 19 May 2022 - Consumer staples and discretionary stocks are leading the dive on the Australian sharemarket, shrugging off the improved labour market, giving back 3 days of gains.
Market Reports / by Lauren Evans - 7 days ago China's economy slumps in April: ASX closes 0.3% higher 16 May 2022 - Australian shares struggled to maintain their early morning rally after China revealed that it had suffered an 11.1 per cent drop in retail sales during April, which …
Market Reports / by Melissa Darmawan - 13 days ago Pendal pops on 1H profit beat: ASX falls for 3rd straight day, tumbling 1.3% at noon 10 May 2022 - Resources stocks are pulling the index lower for a third straight day as investors continue to sell out stocks on concerns around the impact of rising interest rates …
Market Reports / by Lauren Evans - 21 days ago Tech leads ASX tumble, Travel stocks lift: Aus shares close 1.2% lower 02 May 2022 - The ASX had a rough session today ahead of the interest rate outcome tomorrow from the Reserve Bank of Australia. Meanwhile, a weak lead from Wall Street sent Aussie …
Market Reports / by Lauren Evans - 26 days ago Tech shares tumble while energy leads: ASX closes 0.8% lower 27 Apr 2022 - Australian inflation came in hotter-than-expected today, with trimmed mean well above the RBA's 2% to 3% target band and firming bets the central bank will begin lift…
Market Reports / by Melissa Darmawan - A month ago S&P 500 gains 8% in 2-weeks, best run since 2020, Rio, FMG, Macquarie, Scentre on watch: ASX to rise 28 Mar 2022 - Global markets closed mixed on Friday, rising US treasury bond yields boosted financials though hurt growth stocks while rising commodity prices limited losses. An at…
Company News / by Lauren Evans - 2 months ago Imugene (ASX:IMU) receives approval to commence US clinical trial 23 Mar 2022 - Imugene (ASX:IMU) has received approval from the western institutional review board to commence a phase 1 clinical trial of its oncolytic virotherapy candidate, VAXIN…
Market Reports / by Lauren Evans - 2 months ago Block leads tech's surge, Fisher & Paykel tumbles on revenue guidance: ASX up 0.5% at noon 23 Mar 2022 - Following Wall St’s lead, the ASX opened higher and has stayed in positive territory as technology takes the crown from materials. The local bourse continues to be vo…
Market Reports / by Melissa Darmawan - 2 months ago Mining rout prompts a rethink on China's lockdown: ASX down 0.6% at noon 15 Mar 2022 - The banking bulls’ resilient rally amid a surge in treasury yields has taken the spotlight on the ASX, ahead of two central banks to unveil its interest rate decision…
Market Reports / by Lauren Evans - 2 months ago Healthcare leads, Miners & energy fall: ASX closes 0.8% lower 08 Mar 2022 - After see-saw trading this morning, the ASX fell into negative territory in the afternoon session as investors searched for safety amid the US and allies mulling a ba…
Market Reports / by Lauren Evans - 3 months ago ASX rallies, Imugene jumps 10%: ASX down 2.7% over the week 28 Jan 2022 - The ASX rallied in the afternoon, finishing Friday’s session on a positive note after a plummeting week. All sectors closed higher with consumer staples and consumer …
Company News / by Lauren Evans - 3 months ago Imugene (ASX:IMU) reports on two vaccines 28 Jan 2022 - Bio-tech company Imugene (ASX:IMU) has made two announcements today regarding its HER-Vaxx and PD1-Vaxx.
Company News / by Lauren Evans - 6 months ago Stocks of the Hour: Imugene, Beach Energy & Woodside Petroleum 16 Nov 2021 - A snapshot of the stocks on the move, featuring Imugene (ASX:IMU), Beach Energy (ASX:BPT), Woodside Petroleum (ASX:WPL).
Market Reports / by Lauren Evans - 6 months ago ASX falls, Miners drag, Mesoblast drops 5%: ASX down 0.5% at noon 16 Nov 2021 - The ASX is dragging lower this morning as miners weigh on the index. At noon, the S&P/ASX 200 is 0.5% or 37.7 points lower at 7432.4. The SPI futures are pointing to …
Company News / by Michael Luu - A year ago Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment 07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…
Market Reports / by Katrina Bullock - A year ago President Trump contracts Covid-19: Aus shares close 1.4% lower 02 Oct 2020 - The Aussie dollar has toppled, and US futures are looking bleak after confirmation that President Donald Trump and First Lady Melania Trump have contracted Covid-19. …
Company News / by Katrina Bullock - A year ago Imugene (ASX:IMU) secures core US patent 02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth fa…
Company News / by Rachael Jones - 2 years ago Imugene (ASX:IMU) report PD1-Vaxx generates high levels of antibodies 28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.
Market Reports / by Ortenzia Borre - 2 years ago Lithium shares continue to rally: Aus shares close 0.9% higher 14 Jan 2020 - It’s been a positive day of trade for the Australian share market closing 0.9 per cent higher. Kangaroo Island Plantation Timbers (ASX:KPT) report further damage.
Company News / by Anna Napoli - 2 years ago Imugene (ASX:IMU) receives US patent approval for HER-VAxx 14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx cancer treatment.
Market Reports / by Ortenzia Borre - 2 years ago Imugene Limited (ASX:IMU) completes OV acquisition: Aus shares 0.6% lower at noon 18 Nov 2019 - Australian share market dipped on open despite ‘constructive discussions’ regarding the phase-one China and US trade deal between negotiators. Imugene Limited (ASX:IM…
Market Reports / by Jessica Amir - 2 years ago RBA cut rates to historical low, banks under pressure: Aus shares close 0.1% higher 02 Jul 2019 - Australian share market falls after RBA cut rates as expected to 1%, but the ASX200 claws back into positive territory, rising for the 2nd session. Financials lost ov…
Company Presentations / by - 2 years ago Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney 27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vac…
Interviews / by Anna Napoli - 2 years ago Imugene (ASX:IMU) targeting gastric cancer 27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong discusses trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vacci…
